BMC Neurology

Table 2 Spearman correlation coefficients comparing mean changes on the ADAS-Cog, CIBIC-Plus, PGAS and CGAS with mean changes on other outcomes at 6 months

From: The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial

	ADAS-Cog	ADAS-Cog	ADAS-Cog
	improved	no change	worsened	ADAS-Cog	CIBIC-Plus	PGAS*	CGAS*
	(n = 19)	(n = 53)	(n = 23)	(n = 95)	(n = 95)	(n = 95)	(n = 95)
CIBIC-Plus	-0.15	0.15	0.38	0.27	1.00
PGAS*	0.40	-0.32	-0.15	-0.09	-0.59	1.00
Cognition*	0.58	-0.50	-0.32	-0.22	-0.60	0.81	0.58
Function*	0.23	-0.25	-0.07	-0.03	-0.27	0.69	0.22
Behaviour*	-0.33	0.17	-0.17	-0.06	-0.12	0.47	0.18
Leisure*	0.44	-0.32	-0.15	-0.11	-0.50	0.87	0.36
Social*	0.73	-0.32	-0.50	-0.04	-0.52	0.72	0.39
CGAS*	0.33	-0.09	-0.32	-0.22	-0.77	0.52	1.00
Cognition*	0.41	-0.12	-0.27	-0.21	-0.69	0.51	0.84
Function*	0.36	-0.29	0.20	-0.14	-0.60	0.51	0.77
Behaviour*	0.20	0.35	-0.43	-0.30	-0.72	0.41	0.89
Leisure*	-1.00	0.11	0.29	0.12	-0.25	0.32	0.63
Social*	0.15	-0.31	0.21	0.01	-0.76	0.48	0.86
MMSE*	0.59	-0.18	-0.24	-0.35	-0.29	0.24	0.32
PSMS	-0.28	0.00	0.37	0.21	0.51	-0.36	-0.53
IADL	-0.29	0.16	-0.15	0.11	0.37	-0.27	-0.46
CSD	0.24	-0.03	0.39	0.25	0.40	-0.15	-0.53

*Higher scores indicate better performance (the expected direction is positive), otherwise lower scores indicate improvement.

Back to article page

ISSN: 1471-2377

Contact us

General enquiries: journalsubmissions@springernature.com